Fig. 3: Prognostic impact of persistent DTA or CHIP mutations.
Cumulative incidence of relapse according to detectable DTA (a, b) or CHIP (c, d) mutations at pre-HSCT (a, c) and post-HSCT-1m (b, d).
Fig. 3: Prognostic impact of persistent DTA or CHIP mutations. | Blood Cancer Journal
